Diagnostic Power of Galectin-3 in Rheumatic Diseases
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Blood Sampling
2.3. Laboratory Assessments
2.4. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Calabresi, E.; Petrelli, F.; Bonifacio, A.F.; Puxeddu, I.; Alunno, A. One year in review 2018: Pathogenesis of rheumatoid arthritis. Clin. Exp. Rheumatol. 2018, 36, 175–184. [Google Scholar] [PubMed]
- Stern, E.P.; Denton, C.P. The pathogenesis of systemic sclerosis. Rheum Dis Clin. North. Am. 2015, 41, 367–382. [Google Scholar] [CrossRef] [PubMed]
- Zucchi, D.; Elefante, E.; Calabresi, E.; Signorini, V.; Bortoluzzi, A.; Tani, C. One year in review 2019: Systemic lupus erythematosus. Clin. Exp. Rheumatol. 2019, 37, 715–722. [Google Scholar] [PubMed]
- Saroha, A.; Biswas, S.; Chatterjee, B.P.; Das, H.R. Altered glycosylation and expression of plasma alpha-1-acid glycoprotein and haptoglobin in rheumatoid arthritis. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2011, 879, 1839–1843. [Google Scholar] [CrossRef]
- LeRoy, E.C.; Black, C.; Fleischmajer, R.; Jablonska, S.; Krieg, T.; Medsger, T.A., Jr.; Rowell, N.; Wollheim, F. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J. Rheumatol. 1988, 15, 202–205. [Google Scholar]
- Ohshima, S.; Kuchen, S.; Seemayer, C.A.; Kyburz, D.; Hirt, A.; Klinzing, S.; Michel, B.A.; Gay, R.E.; Liu, F.T.; Gay, S.; et al. Galectin-3 and its binding protein in rheumatoid arthritis. Arthritis Rheum. 2003, 48, 2788–2795. [Google Scholar] [CrossRef]
- Henderson, N.C.; Seith, T. The regulation of inflammation by galectin-3. Immunol. Rev. 2009, 230, 160–171. [Google Scholar] [CrossRef]
- Chen, H.Y.; Liu, F.T.; Yang, R.Y. Roles of galectin-3 in immune responses. Arch. Immunol. Ther. Exp. 2005, 53, 497–504. [Google Scholar]
- Li, L.C.; Li, J.; Gao, J. Functions of galectin-3 and its role in fibrotic diseases. J. Pharm. Exp. Ther. 2014, 351, 336–343. [Google Scholar] [CrossRef] [Green Version]
- Dhirapong, A.; Lleo, A.; Leung, P.; Gershwin, M.E.; Liu, F.T. The immunological potential of galectin-1 and -3. Autoimmun. Rev. 2009, 8, 360–363. [Google Scholar] [CrossRef]
- Nishi, Y.; Sano, H.; Kawashima, T.; Okada, T.; Kuroda, T.; Kikkawa, K.; Kawashima, S.; Tanabe, M.; Goto, T.; Matsuzawa, Y.; et al. Role of galectin-3 in human pulmonary fibrosis. Allergol. Int. 2007, 56, 57–65. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Henderson, N.C.; Mackinnon, A.C.; Farnworth, S.L.; Poirier, F.; Russo, F.P.; Iredale, J.P.; Haslett, C.; Simpson, K.J.; Sethi, T. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc. Natl. Acad. Sci. USA 2006, 103, 5060–5065. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aletaha, D.; Neogi, T.; Silman, A.J.; Funovits, J.; Felson, D.T.; Bingham, C.O., 3rd; Birnbaum, N.S.; Burmester, G.R.; Bykerk, V.P.; Cohen, M.D.; et al. Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League against Rheumatism Collaborative Initiative. Arthritis Rheum. 2010, 62, 2569–2581. [Google Scholar] [CrossRef]
- Van den Hoogen, F.; Khanna, D.; Fransen, J.; Johnson, S.R.; Baron, M.; Tyndall, A.; Matucci-Cerinic, M.; Naden, R.P.; Medsger, T.A., Jr.; Carreira, P.E.; et al. Classification criteria for systemic sclerosis: An American College of Rheumatology/European League against Rheumatism Collaborative Initiative. Arthritis Rheum. 2013, 65, 2737–2747. [Google Scholar] [CrossRef] [Green Version]
- Petri, M.; Orbai, A.M.; Alarcon, G.S.; Gordon, C.; Merrill, J.T.; Fortin, P.R.; Bruce, I.N.; Isenberg, D.; Wallace, D.J.; Nived, O.; et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012, 64, 2677–2686. [Google Scholar] [CrossRef]
- De Oliveria, F.L.; Gatto, M.; Bassi, N.; Luisetto, R.; Ghirardello, A.; Punzi, L.; Doria, A. Galectin-3 in autoimmunity and autoimmune diseases. Exp. Biol. Med. 2015, 240, 1019–1028. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- McCullough, P.A. Practical experience using galectin-3 in heart failure. Clin. Chem. Lab. Med. 2014, 52, 1425–1431. [Google Scholar] [CrossRef]
- De Boer, R.A.; Yu, L.; Van Veldhuisen, D.J. Galectin-3 in cardiac remodeling and heart failure. Curr. Heart Fail. Rep. 2010, 7, 1–8. [Google Scholar] [CrossRef]
- Hrynchyshyn, N.; Jourdain, P.; Desnos, M.; Diebold, B.; Funck, F. Galectin-3: A new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure. Arch. Cardiovasc. Dis. 2013, 106, 541–546. [Google Scholar] [CrossRef] [Green Version]
- Mackinnon, A.C.; Gibbons, M.A.; Farnworth, S.L.; Leffler, H.; Nilsson, U.J.; Delaine, T.; Simpson, A.J.; Forbes, S.J.; Hirani, N.; Gauldie, J.; et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am. J. Respir. Crit. Care Med. 2012, 185, 537–546. [Google Scholar] [CrossRef] [Green Version]
- Ezzat, M.H.; El-Gammasy, T.M.; Shaheen, K.Y.; Osman, A.O. Elevated production of Gal-3 is correlated with juvenile idiopathic arthritis disease activity, severity, and progression. Int. J. Rheum. Dis. 2011, 14, 345–352. [Google Scholar] [CrossRef]
- Koca, S.S.; Akbas, F.; Ozgen, M.; Yolbas, S.; Ilhan, N.; Gundogdu, B.; Isik, A. Serum Gal-3 level in systemic sclerosis. Clin. Rheumatol. 2014, 33, 215–220. [Google Scholar] [CrossRef] [PubMed]
- Cao, M.-Y.; Wang, J.; Gao, X.-L.; Hu, Y.-B. Serum galectin-3 concentrations in patients with ankylosing spondylitis. J. Clin. Lab. Anal. 2019, 33, e22914. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.J.; Kang, S.W.; Song, J.K.; Park, J.J.; Bae, Y.D.; Lee, E.Y.; Lee, E.B.; Song, Y.W. Serum Gal-3 and Gal-3 binding protein levels in Behçet’s disease and their association with disease activity. Clin. Exp. Rheumatol. 2007, 25, S41–S45. [Google Scholar] [PubMed]
- Lukyanov, P.; Furtak, V.; Ochieng, J. Galectin-3 interacts with membrane lipids and penetrates the lipid bilayer. Biochem. Biophys. Res. Commun. 2005, 338, 1031–1036. [Google Scholar] [CrossRef]
Age (Years) | Disease Duration | Galectin-3 (ng/mL) | ESR (mm/h) | CRP (mg/L) | PLT (109/L) | HGB (g/dL) | |
---|---|---|---|---|---|---|---|
RA n = 82 | 58.5 20–85 | 9 years 2 months–35 years | 18.75 3.8–50.3 p = 0.000 * | 47.5 6–120 p = 0.000 * p = 0.002 # | 6.4 0.3–151.9 p < 0.001 * | 289 24–839 p = 0.020 * | 11.65 7.9–15.2 p < 0.000 * |
SSc n = 49 | 52 19–77 | 6.5 years 3 months–30 years | 19.4 2.5–64.7 p = 0.000 * | 23 2–100 p = 0.000 * | 2.3 0.2–306.1 p = 0.002 * | 279 193–398 p = 0.008 * | 12.35 8.5–14.8 p < 0.001 * |
SLE n = 18 | 38 23–70 | 9.7 years 1 year–21 years | 19.2 7.5–117.6 p < 0.001 * | 30 10–100 p = 0.000 * | 3.85 0.2–56.5 p < 0.001 * | 228 97–588 p = 0.822 | 12.3 8.8–13.6 p < 0.001 * |
Control group n = 30 | 25 21–54 | - | 9.45 7.3–15 | 5.5 4–8 | 0.65 0.3–3.2 | 235 166–386 | 13.7 11.3–15.5 |
Rheumatic Disease | Test | Cut-off (ng/mL) | Sensitivity (%) | Specificity (%) | ACC (%) | PPV (%) | NPV (%) | AUC ± SE |
---|---|---|---|---|---|---|---|---|
RA | Gal-3 | 15 | 71.1 | 95 | 76 | 98.2 | 46.3 | 0.911 ± 0.030 |
ESR | 8 | 98.6 | 85 | 95.7 | 95.9 | 94.4 | 0.992 ± 0.007 | |
CRP | 3.2 | 72.7 | 95 | 83.3 | 94.1 | 76 | 0.911 ± 0.049 | |
SSc | Gal-3 | 15 | 68.9 | 95 | 76.9 | 96.9 | 57.6 | 0.903 ± 0.038 |
ESR | 8 | 100 | 85 | 88.9 | 70 | 100 | 1.000 ± 0.000 | |
CRP | 3.2 | 43.6 | 95 | 61 | 94.4 | 46.3 | 0.751 ± 0.063 | |
SLE | Gal-3 | 15 | 64.7 | 95 | 81.1 | 91.7 | 76 | 0.859 ± 0.066 |
ESR | 8 | 100 | 85 | 92.3 | 86.4 | 100 | 1.000 ± 0.000 | |
CRP | 3.2 | 61.1 | 95 | 78.9 | 91.7 | 73.1 | 0.839 ± 0.078 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gruszewska, E.; Cylwik, B.; Gińdzieńska-Sieśkiewicz, E.; Kowal-Bielecka, O.; Mroczko, B.; Chrostek, L. Diagnostic Power of Galectin-3 in Rheumatic Diseases. J. Clin. Med. 2020, 9, 3312. https://doi.org/10.3390/jcm9103312
Gruszewska E, Cylwik B, Gińdzieńska-Sieśkiewicz E, Kowal-Bielecka O, Mroczko B, Chrostek L. Diagnostic Power of Galectin-3 in Rheumatic Diseases. Journal of Clinical Medicine. 2020; 9(10):3312. https://doi.org/10.3390/jcm9103312
Chicago/Turabian StyleGruszewska, Ewa, Bogdan Cylwik, Ewa Gińdzieńska-Sieśkiewicz, Otylia Kowal-Bielecka, Barbara Mroczko, and Lech Chrostek. 2020. "Diagnostic Power of Galectin-3 in Rheumatic Diseases" Journal of Clinical Medicine 9, no. 10: 3312. https://doi.org/10.3390/jcm9103312
APA StyleGruszewska, E., Cylwik, B., Gińdzieńska-Sieśkiewicz, E., Kowal-Bielecka, O., Mroczko, B., & Chrostek, L. (2020). Diagnostic Power of Galectin-3 in Rheumatic Diseases. Journal of Clinical Medicine, 9(10), 3312. https://doi.org/10.3390/jcm9103312